

This is the English translation of a Japanese press release published on January 6, 2026. If there are any differences in content or interpretation, the Japanese version shall prevail.

January 6, 2026

Announcement on Withdrawal of the Earnings Forecast for the Fiscal Year Ending February 28, 2026

Hisamitsu Pharmaceutical Co., Inc. (Head office: Tosu City, Saga Prefecture; President and CEO: NAKATOMI, Kazuhide; the “Company”) hereby announces that its board of directors, at its meeting held today, has resolved to withdraw its previously announced consolidated earnings forecast for the fiscal year ending February 28, 2026, which was disclosed on April 10, 2025, as outlined below.

1. Consolidated earnings forecast for the fiscal year ending February 28, 2026

(from March 1, 2025 through February 28, 2026)

(Million yen)

	Net sales	Operating profit	Ordinary profit	Profit attributable to owners of parent	Net income per share
Previous forecast (A)	165,000	20,000	24,300	22,000	306.71
Revised forecast (B)	—	—	—	—	—
Amount of change (B-A)	—	—	—	—	—
Ratio of change (%)	—	—	—	—	—
Results of the previous fiscal year (Fiscal year ended February 29, 2025)	156,006	18,895	24,010	21,758	295.57

2. Reason for withdrawal

As stated in the “Announcement of Implementation of MBO and Recommendation for Tendering Shares” announced today, the Company has resolved at the meeting of its board of directors held today to express its opinion in support of the tender offer (the “Tender Offer”) for our common shares, our stock acquisition rights, and the American Depositary Receipts representing our shares issued in the United States by Citibank, N.A., which will be conducted by TAIYO KOSAN CO., INC. as part of a management buyout, and, among other matters, to recommend that the Company’s shareholders tender their shares in the Tender Offer.

The board of directors’ resolution described above was adopted on the assumption that the Company’s common shares will be delisted, and as a result of the Tender Offer and subsequent procedures, the Company’s common shares are scheduled to be delisted.

In the previous forecast, the Company assumed the recognition of gains from the partial sale of its cross-shareholdings; however, in connection with the announcement of the Tender Offer, the Company’s policy regarding the sale of such cross-shareholdings has become undetermined as of the date hereof.

In light of these circumstances, as it has become difficult to reasonably estimate the current fiscal year’s

performance, the Company has decided to withdraw the consolidated earnings forecast for the fiscal year ending February 28, 2026, which we announced on April 10, 2025.